Recent Data Highlights the Critical Role of the Etiometry Platform in Assessing Compliance and Opportunities for Improvement in Neonatal Oxygen Therapy
News and Press Releases
Abstract presented at the 2025 Pediatric Academic Societies (PAS) Annual Meeting
April 28, 2025 – BOSTON – A recent study conducted at Children’s National Hospital in Washington, D.C., examined the role of Etiometry’s near real-time clinical intelligence platform in assessing neonatal oxygen therapy compliance and identifying potential areas for improvement. The findings were presented this week during the Pediatric Academic Societies (PAS) Annual Meeting in Honolulu.
Using high-fidelity data from 879 preterm neonates over 45 months, researchers confirmed well-documented findings that time spent in hypoxemia (low oxygen levels) increases the odds of developing Bronchopulmonary Dysplasia (BPD), a chronic lung disease that can lead to long-term respiratory issues, while time in hyperoxemia (excess oxygen) is linked to a higher risk of Retinopathy of Prematurity (ROP), a serious eye disorder that can result in lifelong vision impairment or even permanent blindness. These conditions pose significant risks to fragile premature babies, making precise oxygen management critical.
Researchers were able to conduct an observational study assessing how well a neonatal intensive care unit (NICU) adheres to its own oxygen therapy protocols. The study highlights highly actionable, specific opportunities for improvement through future use of the Etiometry platform.
“While the association of hyperoxia and hypoxia with ROP and BPD is well known, this is the first study to measure real-world compliance on such a large dataset. This work quantifies and highlights the significant opportunity for sophisticated tools to improve practice,” says Lamia Soghier, MD, neonatologist at Children’s National.
Additionally, ventilation mode and oxygen therapy are directly streamed into the system, enabling the development of near real-time pathways that flag clinicians to degrees of non-compliance. This continuous feedback helps optimize oxygen therapy management and support targeted interventions to improve compliance, hopefully reducing ROP and BPD in these fragile babies.
This study is part of a broader initiative by Etiometry to collaborate with NICUs nationwide, aiming to enhance outcomes for these vulnerable babies. By leveraging near real-time data and analytics, Etiometry is helping clinicians make more informed decisions at critical moments. This work builds on the recent IVCO2 Index FDA clearance for neonatal care, as well as projects around temperature management and ventilation liberation, further strengthening the company’s commitment to advancing neonatal health.
• 100% of neonatologists would recommend it to a neonatology colleague.
• 100% of users find the Etiometry platform useful for mechanically ventilated NICU patients.
• 80% trust the IVCO2 Index to provide a meaningful assessment of the risk for PaCO2 >60 mmHg or 50 mmHg for mechanically ventilated patients.
• 83% believe the IVCO2 Index has the potential to improve patient outcomes in the NICU.
These findings further support the role of Etiometry’s platform in helping clinicians adhere to protocols and identify actionable opportunities for improving neonatal care. More information can be found at www.etiometry.com.
###
Founded in 2010, Etiometry is a leader in clinical decision-support software designed to help clinicians in intensive care units make data-driven, proactive decisions. By leveraging advanced analytics and AI-powered insights, the company empowers care teams to detect subtle changes in patient conditions, prevent complications, and improve recovery times.
Etiometry has received ten FDA clearances and is trusted by leading healthcare institutions worldwide, including top-ranked academic medical centers and pediatric hospitals. The company is committed to advancing patient safety, improving clinical efficiency, and lowering the cost of care through smarter data utilization.
To learn more, visit www.etiometry.com.
Contacts
Hyedi Nelson
Bellmont Partners
Hyedi@bellmontpartners.com
651-757-7054
Related
Health Tech: Shane Cooke Of Etiometry On How Their Technology Can Make An Important Impact On Our Overall Wellness
An Interview With David Leichner published by Authority Magazine From discussing the five things every health tech founder should know, to the real-world impact of Etiometry’s technology in the ICU, this piece offers a compelling look into the mission driving our team forward every day. Read the full interview HERE
Leveraging AI in Learning Health Systems to improve patient outcomes, reduce costs
Published on DOTmed, by Etiometry’s CEO Shane Cooke It’s no secret that hospitals are facing some of their toughest challenges ever. Workforce shortages and burnout are commonplace and operating budgets are tight. Hospital leaders need to find increasingly creative ways to address these challenges and set themselves up for long-term success. Enter artificial intelligence (AI) technology. […]
HIMSS TV: Etiometry on AI’s role in clinical decision support
In this HIMSS TV interview, Etiometry CEO Shane Cooke dives into the transformative role of AI in clinical decision support—not as a replacement for clinicians, but as a powerful tool to enhance their expertise. Watch the full interview to see how he breaks down how predictive analytics can detect patient deterioration earlier, why AI-driven insights […]